Yuhan Corporation

Sang Koo Park

Moo Young Song

Kang In Na

Tae Hyoung Yoo

Chang Seok Kim

Jae Sun Lee

Heui Il Kang

In Young Ko

Byung Kyu Lee

Heui Ii Kang

Se Cheol Park

Humanized antibodies specifically binding to hTNF-&#x3b1; are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-&#x3b1;-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.

Humanized antibody specific for tumor necrosis factor-alpha

A humanized antibody of the present invention shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenecity. Therefore, the humanized antibody of the present invention can be effectively used for treating chronic hepatitis B and preventing HBV infection of a patient received liver transplantation and vertical transmission from a mother infected with HBV to a fetus.

Humanized antibody against S-surface antigen of hepatitis B virus

An antibody variable region of a monoclonal antibody specifically binding to human tumor necrosis factor-&#x3b1; contains at least one of a heavy chain variable region and a light chain variable region having specific complementarity determining regions therein. A nucleic acid molecule encoding the same, a recombinant vector containing the nucleic acid molecule, and a cell transformed with the recombinant vector are also provided.

Antibody variable region of a monoclonal antibody against human tumor necrosis factor alpha and a gene encoding the same

Nucleic acid molecules encoding human tumor necrosis factor &#x3b1;-specific antibodies

Growing community of inventors

Suwon-si, South Korea

Sang Koo Park